Microarrays have replaced conventional karyotyping as a first-tier test for unbalanced chromosome anomalies in postnatal cytogenetics mainly due to their unprecedented resolution facilitating the detection of submicroscopic copy number changes at a rate of 10–20% depending on indication for testing. A number of studies have addressed the performance of microarrays for chromosome analyses in high risk pregnancies due to abnormal ultrasound findings and reported an excess detection rate between 5% and 10%. In low risk pregnancies, clear pathogenic copy number changes at the submicroscopic level were encountered in 1% or less. Variants of unclear clinical significance, unsolicited findings, and copy number changes with variable phenotypic consequences are the main issues of concern in the prenatal setting posing difficult management questions. The benefit of microarray testing may be limited in pregnancies with only moderately increased risks (advanced maternal age, positive first trimester test). It is suggested to not change the current policy of microarray application in prenatal diagnosis until more data on the clinical significance of copy number changes are available.
References
[1]
Schaaf, C.P.; Wiszniewska, J.; Beaudet, A.L. Copy number and SNP arrays in clinical diagnostics. Annu. Rev. Genom. Hum. Genet. 2011, 12, 25–51, doi:10.1146/annurev-genom-092010-110715.
[2]
Miller, D.T.; Adam, M.P.; Aradhya, S.; Biesecker, L.G.; Brothman, A.R.; Carter, N.P.; Church, D.M.; Crolla, J.A.; Eichler, E.E.; Epstein, C.J.; et al. Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am. J. Hum. Genet. 2010, 86, 749–764, doi:10.1016/j.ajhg.2010.04.006.
[3]
Manning, M.; Hudgins, L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet. Med. 2010, 12, 742–745, doi:10.1097/GIM.0b013e3181f8baad.
[4]
Cooper, G.M.; Coe, B.P.; Girirajan, S.; Rosenfeld, J.A.; Vu, T.H.; Baker, C.; Williams, C.; Stalker, H.; Hamid, R.; Hannig, V.; et al. A copy number variation morbidity map of developmental delay. Nat. Genet. 2011, 43, 838–846, doi:10.1038/ng.909.
[5]
Vissers, L.E.; Stankiewicz, P. Microdeletion and microduplication syndromes. Methods Mol. Biol. 2012, 838, 29–75.
Novelli, A.; Grati, F.R.; Ballarati, L.; Bernardini, L.; Bizzoco, D.; Camurri, L.; Casalone, R.; Cardarelli, L.; Cavalli, P.; Ciccone, R.; et al. Microarray application in prenatal diagnosis: A position statement from the cytogenetics working group of the italian society of human genetics (sigu), November 2011. Ultrasound Obstet. Gynecol. 2012, 39, 384–388.
[9]
Vetro, A.; Bouman, K.; Hastings, R.; McMullan, D.J.; Vermeesch, J.R.; Miller, K.; Sikkema-Raddatz, B.; Ledbetter, D.H.; Zuffardi, O.; van Ravenswaaij-Arts, C.M. The introduction of arrays in prenatal diagnosis: A special challenge. Hum. Mutat. 2012, 33, 923–929, doi:10.1002/humu.22050.
Benn, P.; Cuckle, H.; Pergament, E. Non-invasive prenatal testing for aneuploidy: Current status and future prospects. Ultrasound Obstet. Gynecol. 2013, 42, 15–33, doi:10.1002/uog.12513.
[12]
Simpson, J.L. Invasive procedures for prenatal diagnosis: Any future left? Best Pract. Res. Clin. Obstet. Gynaecol. 2012, 26, 625–638, doi:10.1016/j.bpobgyn.2012.05.007.
[13]
Stumm, M.; Tonnies, H. Fluorescence in situ hybridization techniques in medical diagnostics. Expert Opin. Med. Diagn. 2008, 2, 1381–1390, doi:10.1517/17530050802558899.
[14]
Mann, K.; Ogilvie, C.M. QF-PCR: Application, overview and review of the literature. Prenat. Diagn. 2012, 32, 309–314, doi:10.1002/pd.2945.
[15]
Willis, A.S.; van den Veyver, I.; Eng, C.M. Multiplex ligation-dependent probe amplification (MLPA) and prenatal diagnosis. Prenat. Diagn. 2012, 32, 315–320, doi:10.1002/pd.3860.
[16]
Nicolaides, K.H.; Spencer, K.; Avgidou, K.; Faiola, S.; Falcon, O. Multicenter study of first-trimester screening for trisomy 21 in 75,821 pregnancies: Results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet. Gynecol. 2005, 25, 221–226, doi:10.1002/uog.1860.
[17]
Merz, E.; Thode, C.; Alkier, A.; Eiben, B.; Hackeloer, B.J.; Hansmann, M.; Huesgen, G.; Kozlowski, P.; Pruggmaier, M.; Wellek, S. A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall Med. 2008, 29, 639–645, doi:10.1055/s-2008-1027958.
[18]
Ekelund, C.K.; J？rgensen, F.S.; Petersen, O.B.; Sundberg, K.; Tabor, A.; Danish Fetal Medicine Research Group. Impact of a new national screening policy for Down’s syndrome in Denmark: Population based cohort study. BMJ 2008, 337, a2547, doi:10.1136/bmj.a2547.
[19]
Morain, S.; Greene, M.F.; Mello, M.M. A new era in noninvasive prenatal testing. N. Engl. J. Med. 2013, 369, 499–501, doi:10.1056/NEJMp1304843.
[20]
Gregg, A.R.; Gross, S.J.; Best, R.G.; Monaghan, K.G.; Bajaj, K.; Skotko, B.G.; Thompson, B.H.; Watson, M.S. The Noninvasive Prenatal Screening Work Group of the American College of Medical Genetics and Genomics. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet. Med. 2013, 15, 395–398, doi:10.1038/gim.2013.29.
Benn, P.; Borell, A.; Chiu, R.; Cuckle, H.; Dugoff, L.; Faas, B.; Gross, S.; Johnson, J.; Maymon, R.; Norton, M.; et al. Position statement from the aneuploidy screening committee on behalf of the board of the international society for prenatal diagnosis. Prenat. Diagn. 2013, 33, 622–629, doi:10.1002/pd.4139.
[23]
Pinkel, D.; Segraves, R.; Sudar, D.; Clark, S.; Poole, I.; Kowbel, D.; Collins, C.; Kuo, W.L.; Chen, C.; Zhai, Y.; et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 1998, 20, 207–211, doi:10.1038/2524.
[24]
Vissers, L.E.; de Vries, B.B.; Osoegawa, K.; Janssen, I.M.; Feuth, T.; Choy, C.O.; Straatman, H.; van der Vliet, W.; Huys, E.H.; van Rijk, A.; et al. Array-based comparative genomic hybridization for the genomewide detection of submicroscopic chromosomal abnormalities. Am. J. Hum. Genet. 2003, 73, 1261–1270, doi:10.1086/379977.
Pinto, D.; Darvishi, K.; Shi, X.; Rajan, D.; Rigler, D.; Fitzgerald, T.; Lionel, A.C.; Thiruvahindrapuram, B.; Macdonald, J.R.; Mills, R.; et al. Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. Nat. Biotechnol. 2011, 29, 512–520, doi:10.1038/nbt.1852.
[27]
Tyreman, M.; Abbott, K.M.; Willatt, L.R.; Nash, R.; Lees, C.; Whittaker, J.; Simonic, I. High resolution array analysis: Diagnosing pregnancies with abnormal ultrasound findings. J. Med. Genet. 2009, 46, 531–541, doi:10.1136/jmg.2008.065482.
[28]
Ballif, B.C.; Kashork, C.D.; Saleki, R.; Rorem, E.; Sundin, K.; Bejjani, B.A.; Shaffer, L.G. Detecting sex chromosome anomalies and common triploidies in products of conception by array-based comparative genomic hybridization. Prenat. Diagn. 2006, 26, 333–339, doi:10.1002/pd.1411.
[29]
Filges, I.; Kang, A.; Klug, V.; Wenzel, F.; Heinimann, K.; Tercanli, S.; Miny, P. aCGH on chorionic villi mirrors the complexity of fetoplacental mosaicism in prenatal diagnosis. Prenat. Diagn. 2011, 31, 473–478, doi:10.1002/pd.2721.
[30]
Campbell, C.D.; Eichler, E.E. Properties and rates of germline mutations in humans. Trends Genet. 2013, 29, 575–584, doi:10.1016/j.tig.2013.04.005.
[31]
Wapner, R.J.; Martin, C.L.; Levy, B.; Ballif, B.C.; Eng, C.M.; Zachary, J.M.; Savage, M.; Platt, L.D.; Saltzman, D.; Grobman, W.A.; et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N. Engl. J. Med. 2012, 367, 2175–2184, doi:10.1056/NEJMoa1203382.
[32]
Shaffer, L.G.; Dabell, M.P.; Fisher, A.J.; Coppinger, J.; Bandholz, A.M.; Ellison, J.W.; Ravnan, J.B.; Torchia, B.S.; Ballif, B.C.; Rosenfeld, J.A. Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies. Prenat. Diagn. 2012, 32, 976–985, doi:10.1002/pd.3945.
[33]
Shaffer, L.G.; Rosenfeld, J.A.; Dabell, M.P.; Coppinger, J.; Bandholz, A.M.; Ellison, J.W.; Ravnan, J.B.; Torchia, B.S.; Ballif, B.C.; Fisher, A.J. Detection rates of clinically significant genomic alterations by microarray analysis for specific anomalies detected by ultrasound. Prenat. Diagn. 2012, 32, 986–995, doi:10.1002/pd.3943.
[34]
Mademont-Soler, I.; Morales, C.; Soler, A.; Martinez-Crespo, J.M.; Shen, Y.; Margarit, E.; Clusellas, N.; Obon, M.; Wu, B.L.; Sanchez, A. Prenatal diagnosis of chromosomal abnormalities in fetuses with abnormal cardiac ultrasound findings: Evaluation of chromosomal microarray-based analysis. Ultrasound Obstet. Gynecol. 2013, 41, 375–382, doi:10.1002/uog.12372.
[35]
Hillman, S.C.; McMullan, D.J.; Hall, G.; Togneri, F.S.; James, N.; Maher, E.J.; Meller, C.H.; Williams, D.; Wapner, R.J.; Maher, E.R.; et al. Use of prenatal chromosomal microarray: Prospective cohort study and systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2013, 41, 610–620, doi:10.1002/uog.12464.
[36]
De Wit, M.C.; Srebniak, M.I.; Govaerts, L.C.; van Opstal, D.; Galjaard, R.J.; Go, A.T. The additional value of prenatal genomic array testing in fetuses with (isolated) structural ultrasound abnormalities and a normal karyotype: A systematic review of the literature. Ultrasound Obstet. Gynecol. 2013, doi:10.1002/uog.12575.
[37]
Breman, A.; Pursley, A.N.; Hixson, P.; Bi, W.; Ward, P.; Bacino, C.A.; Shaw, C.; Lupski, J.R.; Beaudet, A.; Patel, A.; et al. Penatal chromosomal microarray analysis in a diagnostic laboratory; experience with >1000 cases and review of the literature. Prenat. Diagn. 2012, 32, 351–361, doi:10.1002/pd.3861.
[38]
Callaway, J.L.; Shaffer, L.G.; Chitty, L.S.; Rosenfeld, J.A.; Crolla, J.A. The clinical utility of microarray technologies applied to prenatal cytogenetics in the presence of a normal conventional karyotype: A review of the literature. Prenat. Diagn. 2013, doi:10.1002/pd.4209.
[39]
Hillman, S.C.; McMullan, D.J.; Silcock, L.; Maher, E.R.; Kilby, M.D. How does altering the resolution of chromosomal microarray analysis in the prenatal setting affect the rates of pathological and uncertain findings? J. Matern. Fetal Neonatal Med. 2013, doi:10.3109/14767058.2013.825601.
[40]
Ganesamoorthy, D.; Bruno, D.L.; McGillivray, G.; Norris, F.; White, S.M.; Adroub, S.; Amor, D.J.; Yeung, A.; Oertel, R.; Pertile, M.D.; et al. Meeting the challenge of interpreting high-resolution single nucleotide polymorphism array data in prenatal diagnosis: Does increased diagnostic power outweigh the dilemma of rare variants? BJOG 2013, 120, 594–606, doi:10.1111/1471-0528.12150.
[41]
Srebniak, M.I.; Mout, L.; van Opstal, D.; Galjaard, R.J. 0.5 Mb array as a first-line prenatal cytogenetic test in cases without ultrasound abnormalities and its implementation in clinical practice. Hum. Mutat. 2013, 34, 1298–1303, doi:10.1002/humu.22355.
[42]
Shaffer, L.G.; Dabell, M.P.; Rosenfeld, J.A.; Neill, N.J.; Ballif, B.C.; Coppinger, J.; Diwan, N.R.; Chong, K.; Shohat, M.; Chitayat, D. Referral patterns for microarray testing in prenatal diagnosis. Prenat. Diagn. 2012, 32, 344–350, doi:10.1002/pd.3856.
[43]
Fiorentino, F.; Napoletano, S.; Caiazzo, F.; Sessa, M.; Bono, S.; Spizzichino, L.; Gordon, A.; Nuccitelli, A.; Rizzo, G.; Baldi, M. Chromosomal microarray analysis as a first-line test in pregnancies with a priori low risk for the detection of submicroscopic chromosomal abnormalities. Eur. J. Hum. Genet. 2013, 21, 725–730, doi:10.1038/ejhg.2012.253.
[44]
Verhagen, J.M.; Diderich, K.E.; Oudesluijs, G.; Mancini, G.M.; Eggink, A.J.; Verkleij-Hagoort, A.C.; Groenenberg, I.A.; Willems, P.J.; du Plessis, F.A.; de Man, S.A.; et al. Phenotypic variability of atypical 22q11.2 deletions not including tbx1. Am. J. Med. Genet. A 2012, 158a, 2412–2420, doi:10.1002/ajmg.a.35517.
[45]
Dixit, A.; McKee, S.; Mansour, S.; Mehta, S.G.; Tanteles, G.A.; Anastasiadou, V.; Patsalis, P.C.; Martin, K.; McCullough, S.; Suri, M.; et al. 7q11.23 Microduplication: A recognizable phenotype. Clin. Genet. 2013, 83, 155–161.
[46]
Pichert, G.; Mohammed, S.N.; Ahn, J.W.; Ogilvie, C.M.; Izatt, L. Unexpected findings in cancer predisposition genes detected by array comparative genomic hybridisation: What are the issues? J. Med. Genet. 2011, 48, 535–539, doi:10.1136/jmg.2010.087593.
[47]
McGillivray, G.; Rosenfeld, J.A.; McKinlay Gardner, R.J.; Gillam, L.H. Genetic counselling and ethical issues with chromosome microarray analysis in prenatal testing. Prenat. Diagn. 2012, 32, 389–395, doi:10.1002/pd.3849.
[48]
ACOG Practice Bulletin No. 77: Screening for fetal chromosomal abnormalities. Obstet. Gynecol. 2007, 109, 217–227.
[49]
Bui, T.H.; Vetro, A.; Zuffardi, O.; Shaffer, L.G. Current controversies in prenatal diagnosis 3: Is conventional chromosome analysis necessary in the post-array CGH era? Prenat. Diagn. 2011, 31, 235–243, doi:10.1002/pd.2722.
